MBD

About Us

Professional company for 3D cell culture platform specialized in anticancer drug sensitivity and efficacy/toxicity test.

MBD History

Introducing the footsteps of MBD's growth through constant innovation and continuous research.

  • 2021
  • DecAwarded the 2021 Venture Award(the corporate sector, the Minister of SMEs and Startups)
  • NovTechnology innovation-oriented SMEs(Inno-Biz) Certification(the Ministry of SMEs and Startups)
  • Oct"3 dimension cancer drug sensitivity" service(Health Insurance Review & Assessment Service)
  • OctSelected as an international joint technology development project in 2021 years (Ministry of Trade, Industry and Energy, 3 years)
  • SepKOREA Bio-Leading Company Grand prize(3 consecutive years)
  • MarObtained CE certification(EC Declaration of Conformity, Phenotrack BCA)
  • FebIPO representative organizer contract
  • FebVC series B investment attraction (11.5 billion won)
  • 2020
  • DecEstablished a joint lab at Luxembourg Institute of Health (LIH)
  • DecSelected as an advanced technology center institute in 2020 (Ministry of Science and ICT)
  • DecSelected as a strategic start-up task(breast cancer) (Ministry of SMEs and Startups)
  • SepSelected as a whole-cycle medical device research and development project(head and neck cancer/ovarian cancer) by Pan-government
  • AugKOREA Bio-Leading Company Grand prize(2 consecutive years)
  • JulSelected as a radiation high-value new material development project(Ministry of Science and ICT)
  • JunObtained KFDA Medical device certification(Calcein AM Kit)
  • MaySelected as a 2020 technology commercialization capability enhancement project (Ministry of Science and ICT)
  • FebJoint development contract for rare cancer treatment based on AI Model (Azothbio)
  • 2019
  • DecAwarded Small and Medium Business excellence Partner Award (Korea Basic Science Institute)
  • DecObtained IVD CE certification approval (ASFA Scanner)
  • NovObtained ISO 13485 certification
  • SepGrand prize awarded as 2019 Korea Biology leading company
  • SepObtained FDA medical device certification (ASFA Spotter)
  • JunAttend NIH Spring Exhibit 2019 (USA, Bethesda) Display/PR
  • JunObtained FDA medical device certification (ASFA Scanner)
  • MaySelected as a start-up leap package business (Ministry of Health and Welfare)
  • AprKFDA medical device manufacture and certification approval (ASFA Scanner)
  • FebSelected as an investment-related project for public technology transfer company (Ministry of Science and ICT)
  • JanAttracting VC Series A investment (10 Billion won)
  • 2018
  • DecSet-up liver cancer patient personalized drug screening platform for the Precision medicine (Singapore)
  • SepKsilink-LIH- MBD research collaboration agreement for personalized cancer drug screening
  • JunSelected as a business growth technology development business (Ministry of SMEs and Startups)
  • FebSLAS exhibition (USA, San Diego) Display /PR
  • 2017
  • OctSelected for military substitute service designated company(Military Manpower Administration)
  • SepSelected as pharmaceutical biotechnology advanced technology business (Gyeonggido Business & Science Accelerator)
  • SepSelected for industry-academic cooperation technology development project (Ministry of SMEs and Startups)
  • JunAttracting VC seeding investment (2 Billion won)
  • FebVenture capital certification
  • JanSinged sales representative agreement with ThermoFisher Scientific
  • JanSelected as KRISS family corporation and technology leading hidden champion training project (Korea Research Institute of Standards and Science)
  • 2016
  • DecSelected as KBSI family corporation (Korea Basic Science Institute)
  • OctFrance Ksilink, Export 3D cell culture /drug screening device (First)
  • 2015
  • JanEstablished MBD Co., Ltd.